Simcere Pharmac Grp Stock Beneish M Score
| S2P Stock | EUR 0.81 0.01 1.22% |
SIMCERE |
At this time, SIMCERE PHARMAC's M Score is inapplicable. The earnings manipulation may begin if SIMCERE PHARMAC's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by SIMCERE PHARMAC executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of SIMCERE PHARMAC's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.84
Beneish M Score - Inapplicable
Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
About SIMCERE PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SIMCERE PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SIMCERE PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SIMCERE PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SIMCERE Stock
SIMCERE PHARMAC financial ratios help investors to determine whether SIMCERE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SIMCERE with respect to the benefits of owning SIMCERE PHARMAC security.